|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia显示文摘 | Roth EM McKenney JM Hanotin C | 2012 | N Engl J Med2012，367，20： | 1 |
| 2 | Safety and tolerability of dalcetrapib (RO4607381/JTT-705):results from a 48-week trial显示文摘 | Stein EA Roth EM Rhyne JM | 2010 | Eur Heart J2010，31，4： | 1 |
| 3 | Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients wilb hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial显示文摘 | Roth EM Taskinen MR Ginsberg HN | 2014 | Int J Cardiol2014，176，1： | 1 |
| 4 | Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia显示文摘 | Roth EM McKenney JM Hanotin C | | 0，，： | 1 |
| 5 | Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia显示文摘 | ROTH EM McKENNEY JM HANOTIN C | 2012 | N Engl J Med2012，367，20： | 1 |
| 6 | The effects of postoperative corticosteroids on trabeculectomy and the clinical course of glaucoma:five-year follow-up study显示文摘 | Roth SM Spaeth GL Starita RJ Birbillis EM Steinmann WC | 1991 | Ophthalmic Surg1991，22，12： | 1 |
| 7 | Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia 显示文摘 | Roth EM McKenney JM Hanotin C | 2012 | N Engl J Med2012，367，20： | 1 |
| 8 | Atorvastatin with orwithout an antibody to PCSK9 in primary hypercholest- erolemia显示文摘 | ROTH EM McKENNEY JM HANOTIN C | 2012 | N Engl J Med2012，367，20： | 1 |
| 9 | Signaling the brain in systemic intrlammation: role of sensory circumventricular organs显示文摘 | Roth J Harre EM Rummel C | 2004 | Front Biosci2004，9，： | 1 |
| 10 | Year two assessment of fenofibric acid and moderate-dose statin combination:a phase3,open-label,extension study显示文摘 | Kipnes MS Roth EM Rhyne JM | 2010 | Clin Drug Investig2010，30，1： | 1 |
| 11 | Slope stability analysis by strength reduction显示文摘 | Dawson EM Roth W H Drescher A | 1999 | Geotechnique1999，49，6： | 1 |
| 12 | Attainment of goal/de- sirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination thera-py : a pooled analysis of controlled studies 显示文摘 | Roth EM Rosenson RS Jones PH | 2012 | J Clin Lipi- dol2012，6，6： | 1 |
| 13 | The treatment of complex dural arteriovenous fistulae through cranial base techniques 显示文摘 | Kattner KA Roth TC Nardone EM | 2004 | Neurol India2004，52，3： | 1 |
| 14 | Molecular events in bronchogenic carcinoma and their implications for therapy显示文摘 | Toloza EM Roth JA Swisher SG | 2000 | Semin Surg Oncol2000，18，： | 1 |
| 15 | Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia显示文摘 | Roth EM McKenney JM Hanotin C | 2012 | N Engl J Med2012，367，20： | 1 |
| 16 | ODYSSEY MONO:effect of a1irocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks 显示文摘 | Roth EM McKenney JM | 2015 | Future Cardiol2015，11，1： | 1 |
| 17 | Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody显示文摘 | ROTH EM DILLER P | 2014 | Future Cardiol2014，10，2： | 1 |
| 18 | Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:results of a 24 week,doubleblind,randomized phase 3 trial显示文摘 | ROTH EM TASKINEN MR GINSBERG HN | 2014 | Int J Cardiol2014，176，1： | 1 |
| 19 | Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, doubleblind, randomized Phase 3 trial显示文摘 | ROTH EM TASKINEN M R GINSBERG H N | 2014 | IntJ Cardiol2014，，： | 1 |
| 20 | Patient and Physician Perspectives on Mode of Administration of the PC- SK9 Monoclonal Antibody Alirocumab, an Injectable Medi- cation to Lower LDL-C Levels 显示文摘 | Roth EM Bujas-Bobanovic M Louie M J | 2015 | Clinical Therapeutics2015，37，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员